134 related articles for article (PubMed ID: 36048569)
1. Double-, single- and none-carbapenem-containing regimens for the treatment of carbapenem-resistant Enterobacterales (CRE) bloodstream infections: a retrospective cohort.
Rigatto MH; Ramos F; Barros A; Pedroso S; Guasso I; Gonçalves L; Bergo P; Zavascki AP
J Antimicrob Chemother; 2022 Oct; 77(11):3118-3125. PubMed ID: 36048569
[TBL] [Abstract][Full Text] [Related]
2. Rectal culture could predict carbapenem-resistant organism bloodstream infection and reduce the mortality in haematological patients: A retrospective cohort study.
Gao S; Yan R; Zhang S; Li L; Zhang R; Fan J; Qin J; Peng Y; Wan D; Cao W; Bian Z
J Glob Antimicrob Resist; 2024 Mar; 36():96-104. PubMed ID: 38128727
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant
Chen L; Han X; Li Y; Li M
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0069821. PubMed ID: 34228539
[TBL] [Abstract][Full Text] [Related]
4. Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: Insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48.
Karnmueng P; Montakantikul P; Paiboonvong T; Plongla R; Chatsuwan T; Chumnumwat S
Clin Transl Sci; 2024 Jun; 17(6):e13855. PubMed ID: 38853376
[TBL] [Abstract][Full Text] [Related]
5. Adding double carbapenem therapy to the armamentarium against carbapenem-resistant Enterobacteriaceae bloodstream infections.
White BP; Patel S; Tsui J; Chastain DB
Infect Dis (Lond); 2019 Mar; 51(3):161-167. PubMed ID: 30663923
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes and Treatment Strategies in Patients With Non-Carbapenemase-producing Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacterales Infections.
Debnath A; Pillinger KE; Martin AJ; Dobrzynski D; Cameron A; Shulder S
Ann Pharmacother; 2023 Jul; 57(7):803-812. PubMed ID: 36268974
[TBL] [Abstract][Full Text] [Related]
8. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
[TBL] [Abstract][Full Text] [Related]
9. Carbapenem-resistant
Ruvinsky S; Voto C; Roel M; Deschutter V; Ferraro D; Aquino N; Reijtman V; Galvan ME; Motto E; García M; Sarkis C; Bologna R
Front Public Health; 2022; 10():983174. PubMed ID: 36091556
[TBL] [Abstract][Full Text] [Related]
10. The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study.
Ngoma N; Perovic O; de Voux A; Musekiwa A; Shuping L;
BMC Infect Dis; 2024 Jun; 24(1):561. PubMed ID: 38840122
[TBL] [Abstract][Full Text] [Related]
11. Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network).
Falcone M; Tiseo G; Carbonara S; Marino A; Di Caprio G; Carretta A; Mularoni A; Mariani MF; Maraolo AE; Scotto R; Dalfino L; Corbo L; Macera M; Medaglia AA; d'Errico ML; Gioè C; Sgroi C; Del Vecchio RF; Ceccarelli G; Albanese A; Buscemi C; Talamanca S; Raponi G; Foti G; De Stefano G; Franco A; Iacobello C; Corrao S; Morana U; Pieralli F; Gentile I; Santantonio T; Cascio A; Coppola N; Cacopardo B; Farcomeni A; Venditti M; Menichetti F;
Clin Infect Dis; 2023 Jun; 76(12):2059-2069. PubMed ID: 36801828
[TBL] [Abstract][Full Text] [Related]
12. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
[TBL] [Abstract][Full Text] [Related]
13. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.
Stewardson AJ; Marimuthu K; Sengupta S; Allignol A; El-Bouseary M; Carvalho MJ; Hassan B; Delgado-Ramirez MA; Arora A; Bagga R; Owusu-Ofori AK; Ovosi JO; Aliyu S; Saad H; Kanj SS; Khanal B; Bhattarai B; Saha SK; Uddin J; Barman P; Sharma L; El-Banna T; Zahra R; Saleemi MA; Kaur A; Iregbu K; Uwaezuoke NS; Abi Hanna P; Feghali R; Correa AL; Munera MI; Le TAT; Tran TTN; Phukan C; Phukan C; Valderrama-Beltrán SL; Alvarez-Moreno C; Walsh TR; Harbarth S
Lancet Infect Dis; 2019 Jun; 19(6):601-610. PubMed ID: 31047852
[TBL] [Abstract][Full Text] [Related]
14. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
Li C; Li Y; Zhao Z; Liu Q; Li B
J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
[TBL] [Abstract][Full Text] [Related]
15. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
[TBL] [Abstract][Full Text] [Related]
16. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children.
Ara-Montojo MF; Escosa-García L; Alguacil-Guillén M; Seara N; Zozaya C; Plaza D; Schuffelmann-Gutiérrez C; de la Vega Á; Fernández-Camblor C; Ramos-Boluda E; Romero-Gómez MP; Ruiz-Carrascoso G; Losantos-García I; Mellado-Peña MJ; Gómez-Gil R
J Antimicrob Chemother; 2021 Jan; 76(1):220-225. PubMed ID: 33038895
[TBL] [Abstract][Full Text] [Related]
18. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infection in Solid Organ Transplant Recipients.
Anesi JA; Lautenbach E; Thom KA; Tamma PD; Blumberg EA; Alby K; Bilker WB; Werzen A; Ammazzalorso A; Tolomeo P; Omorogbe J; Pineles L; Han JH
Transplantation; 2023 Jan; 107(1):254-263. PubMed ID: 35856636
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and risk factors for neonatal bloodstream infection due to carbapenem-resistant Enterobacteriaceae: A single-centre Chinese retrospective study.
Fang P; Gao K; Yang J; Li T; Sun Q; Shan Z; Wang Y
J Glob Antimicrob Resist; 2024 Jun; 37():28-36. PubMed ID: 38412919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
